Temozolomide

目录号:S1237 别名: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。

规格 价格 库存 购买数量  
RMB 521.97 现货
RMB 574.37 现货
RMB 1411.95 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献18篇:

客户使用该产品的7个实验数据:

  • C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

  • D, Scramble (SCR), H82, H865, and H1836 cells were treated with AZD1775 (100 nmol/L) and temozolomide (1 μmol/L) for 24 hours; WEE1 KD cells were treated with just temozolomide (1 μmol/L) for 24 hours. The cells were lysed at 24 hours and subjected to Western blot analysis for phosphorylated WEE1 (pWEE1_S642), pCDC2_Y15 (WEE1 downstream effector), γH2AX (DNA damage marker), PH3 (mitotic marker), cleaved caspase-3 (apoptotic marker), and actin (loading control). E, SCR and WEE1 KD H82, H865, and H1836 cells were treated as described in D and subjected to Western blot analysis for DNA repair markers pATM_S1981, MRE11, RAD51, and E2F1. Actin was used as a loading control.

    Clin Cancer Res, 2017, 23(20):6239-6253. Temozolomide purchased from Selleck.

  • Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

  • J Control Release, 2018, 269:245-257. Temozolomide purchased from Selleck.

  • Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

  • Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

  • Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

产品安全说明书

DNA/RNA Synthesis抑制剂选择性比较

生物活性

产品描述 Temozolomide(TMZ)是一种单功能的SN-1烷化剂,修饰DNA环上的氮原子以及环外氧基团。在生理pH值下,TMZ转化为活性产物MTIC、降解为methyldiazonium cation,后者再将甲基转移到DNA, 阻碍DNA复制启动,诱使细胞凋亡,是一种DNA损伤诱导剂。
特性 Methazolastone是第二代烷化剂。
靶点
DNA replication [1]
(L-1210, L-1210/BCNU cells)
体外研究

Methazolastone引起DNA碱不稳定位点的形成,其在L-1210和L-1210/BCNU细胞系中以相似数量存在,并且以相似比率修复。在L-1210中,methazolastone诱导细胞阻滞在SL-G2-M期,但在L-1210/BCNU中无此作用。[1]对化疗敏感与耐受的细胞(D54-R 和 U87-R)对Methazolastone的敏感性在高氧情况下被显著增强。Methazolastone和高氧均与ERK p44/42 MAPK (Erk1/2)磷酸化的增加相关,但是在D54-R细胞中增加程度较低,表明Erk1/2可能参与高氧与Methazolastone介导的细胞死亡的调节。高氧增强Methazolastone诱导细胞凋亡在GBM细胞中产生的细胞毒性,可能是通过MAPK相关的途径发挥作用。[2] Methazolastone诱导单核细胞中DNA损伤应答通路ATM-Chk2 和ATR-Chk1,导致p53活化。[3]长期Methazolastone暴露导致获得性Methazolastone耐药,并提高miR-21表达。[4] Methazolastone治疗引起内质网(ER)应激,增加GADD153和GRP78蛋白质表达,并减少caspase 12前体蛋白质。Methazolastone通过线粒体损伤和内质网应激依赖机制诱导自吞噬,以保护神经胶质瘤细胞。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPGe3ZXPDhiaB?= MlvsTWM2OD1zM{muNlDjiIoEsfMAjVUvQTVizszN NIm1VG4zPTl4MEK4Ni=>
KellyCis83 M1TMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrYT4c1QCCq MY\JR|UxRTJ3MT6wNQKBkcLz4pEJNVUvPzVizszN NH;oVYIzPTl4MEK4Ni=>
SK-N-AS M4DkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGexfW01QCCq MWfJR|UxRTJ{Nz63NQKBkcLz4pEJNlIvOTVizszN MVyyOVk3ODJ6Mh?=
SK-N-ASCis24 MmHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX60PEBp NXjTXHI3UUN3ME20PFAvPjEkgJpCtgKBkTFyMT6xOUDPxE1? M2[1RlI2QTZyMkiy
CHP-212 M3zx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljZOFghcA>? NIrRWoJKSzVyPUeuPVfjiIoEsfMAjVAvPjlizszN NGfXdJIzPTl4MEK4Ni=>
CHP-212Cis100 NH\0VGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUi0PEBp MlrVTWM2OD17LkW15qCKyrIkgJmwMlg5KM7:TR?= MkfpNlU6PjB{OEK=
U87  M1XLVWZ2dmO2aX;uJGF{e2G7 MkexNVAxKM7:TR?= NX;jUGV[OjRvN{KgbC=> M2fFTolv\HWlZYOgSINTOSCneIDy[ZN{cW:w MnLENlU5ODh6Nki=
LN229 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDVNE02OCEQvF2= NF2xdXNKSzVyPUG2JO69VQ>? Ml33NlU4PTB{N{O=
TR-LN229 M2fiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHLNE02OCEQvF2= M{TubmlEPTB;N{eg{txO MW[yOVc2ODJ5Mx?=
U87  NVTXN5dWSXCxcITvd4l{KEG|c3H5 MnHVNQKBmzJyMPMAjeK2VQ>? M2HHcVI1KGh? M3LiXYVvcGGwY3XzJGNSKGmwZIXj[YQh[XCxcITvd4l{ MUSyOVY5OTZ4OB?=
U251MG MXjBdI9xfG:|aYOgRZN{[Xl? NGTDV3EyODEEoN88US=> M2ntW|Q5KGh? NWXxSphFWEKV MWXpcoR2[2W|IHHwc5B1d3Orcx?= Mm\6NlU3QDB2NkS=
U87MG M1LVS2Fxd3C2b4Ppd{BCe3OjeR?= MXKxNFDDqM7:TR?= NUXEdmE6PDhiaB?= MVnQRnM> MnW1bY5lfWOnczDhdI9xfG:|aYO= NHzpZVYzPTZ6MES2OC=>
U87 NXTQVY03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;SOVAuOzVyIN88US=> M3rRVlQ5yqCqwrC= MXnpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> NUHMdXNTOjV3NUSyNlM>
U118  M{LnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPwT3A2OC1|NUCg{txO NU\xbHNXPDkEoHlCpC=> MWrpcohq[mm2czDj[YxtKGe{b4f0bEB{dGmpaITsfS=> MUGyOVU2PDJ{Mx?=
U87 M3:2d2Z2dmO2aX;uJGF{e2G7 NYrZTld4OjVyL{O1NEDPxE1? NHfRWFE1QMLiaNMg M4H4boVvcGGwY3XzJHROYC2rbnT1Z4VlKHBvUFvDMZBidiCmZXPy[YF{\Q>? MkH1NlU2PTR{MkO=
U118  MX7GeY5kfGmxbjDBd5NigQ>? NYOxbmkzOjVyL{O1NEDPxE1? NF\lU4k1QMLiaNMg MV;lcohidmOnczDUUXgucW6mdXPl[EBxNVCNQz3wZY4h\GWlcnXhd4U> MmG2NlU2PTR{MkO=
U87 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;SNlUxNzN3MDFOwG0> MX60POKhcMLi MUPpcoNz\WG|ZYOgeIhmKHCncnPlcpRi\2Vib3[gZ4VtdHNiaX6gV{BidmRiR{KvUeKh[2:2cnXheIVlKHerdHigWG1Z Moe0NlU2PTR{MkO=
A375 NVjR[nQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DsSFQ5yqCqwrC= MoS4TWM2OD1{NkWg{txO MmK4NlU2OjR3NUK=
A2058 MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvx[XE1QMLiaNMg M4\Nd2lEPTB;MUKg{txO MYeyOVUzPDV3Mh?=
M238 NYrPO|RyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm1ZpprPDkEoHlCpC=> MVHJR|UxRTRyIN88US=> NHPHTmgzPTV{NEW1Ni=>
M249 MoTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\sOlQ5yqCqwrC= MljpTWM2OD1{NUSg{txO NYDEUoN7OjV3MkS1OVI>
M21 M1P2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfNdVU1QMLiaNMg MmPsTWM2OD1{MkGg{txO M{\GU|I2PTJ2NUWy
U251 M2ruPWN6fG:2b4jpeJkhSXO|YYm= M4nJ[lIxKM7:TdMg M{H5OlQ5yqCqwrC= NIXVdoNz\WS3Y3Xkd{B1cGVicHXyZ4VvfGGpZYOgc4Yh[2:ub37p[ZMh\m:{bXXk MXSyOVQ{PDN6MR?=
LN229 M{DCUWN6fG:2b4jpeJkhSXO|YYm= NXvlPFhFOjBizszNxsA> NHnBPVY1QMLiaNMg MlHkdoVlfWOnZIOgeIhmKHCncnPlcpRi\2W|IH;mJINwdG:waXXzJIZwem2nZB?= NGi4W3kzPTR|NEO4NS=>
U373MG-LUC M4\IOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzkNZhNPzJiaB?= NV6xeZhIUUN3ME62NFAh|ryP MXmyOVQ{OTl3Mx?=
U87  NHjnN3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYi3NHVxOjVvMkCwJO69VQ>? MlfaOFjDqGkEoB?= MonqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NYS0e4R{OjV2MEC3OFU>
U251 M3n1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfIUnUzPS1{MECg{txO MVW0POKhcMLi NXfsZlc1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{TWb|I2PDByN{S1
U251 MnvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxNFAuPDByIN88US=> Mo\UO|IwQTZiaB?= M3LGPJRp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= NUDsRWVkOjV|N{WyO|E>
U373 M2XQbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjBT2QyODBvNECwJO69VQ>? MnPJO|IwQTZiaB?= MXP0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NYjCNox4OjV|N{WyO|E>
U343 M2r3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxNFAuPDByIN88US=> NXvjXpY4PzJxOU[gbC=> MoHjeIhmKGGwdHmtdJJwdGmoZYLheIl3\SCnZn\lZ5Qh[2GwIHLlJIVvcGGwY3XkJIJ6KGexc4P5dI9tKGWwaHHuZ4VlKMLi M1;GdlI2Ozd3Mkex
U87MG-luc2 NGTn[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTnVIgyODBvNECwJO69VQ>? NFPDZ3g4Oi97NjDo MVL0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NEO5PWkzPTN5NUK3NS=>
U87 MkL3SpVv[3Srb36gRZN{[Xl? MUGyNFAh|ryP MYm0PEBp MW\pcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v NYDNc|M{OjV|M{e3NlE>
U251 M2PDZWZ2dmO2aX;uJGF{e2G7 NHL0NVkzODBizszN MVy0PEBp Mk\DbY5kemWjc3XzJGJTS0N|IH3SUmEh\XiycnXzd4lwdg>? NVfubXpkOjV|M{e3NlE>
A172 MlHRSpVv[3Srb36gRZN{[Xl? MnPkNlAxKM7:TR?= M12yeFQ5KGh? NXnQWFVMcW6lcnXhd4V{KEKUQ1OzJI1TVkFiZYjwdoV{e2mxbh?= NUe1R5lIOjV|M{e3NlE>
U251 NFr2W2NHfW6ldHnvckBCe3OjeR?= NGX1XFIzODBizszN Mnn0OFghcA>? M3nTTolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ? M2HrTVI2OzN5N{Kx
A172 NUXmZndjTnWwY4Tpc44hSXO|YYm= M2[xSVIxOCEQvF2= NF7GblA1QCCq MUfpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gRnJESTFuIFLSR2EzNCCUQVS1NUBidmRiRlHOR2Qz MU[yOVM{Pzd{MR?=
U87 NILvOXFHfW6ldHnvckBCe3OjeR?= NHvJcZIzODBizszN M2rTWlI1Nzd{L{GyNEBp NYezeGE{cW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 MknmNlU{Ozd5MkG=
U251 Mlf1SpVv[3Srb36gRZN{[Xl? M3TP[lIxOCEQvF2= Mn\yNlQwPzJxMUKwJIg> M4W3d4lv[3KnYYPld{DPu0h{QWig[o9kcSCob4LtZZRqd25idHnt[U1l\XCnbnTlcpRtgQ>? MnHHNlU{Ozd5MkG=
A172 MnnpSpVv[3Srb36gRZN{[Xl? NUG0fpRsOjByIN88US=> MofMNlQwPzJxMUKwJIg> MUPpcoNz\WG|ZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9vKHSrbXWt[IVx\W6mZX70cJk> MmHTNlU{Ozd5MkG=
SNB19V NGXzdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[zW3k4KGR? MUfEUXNQ NH7yXYRIUTVyPUO1MlfDuTF{IN88US=> MnPENlUzPzd2NEG=
SNB19M M3HXPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPiO{Bl NELwNmJFVVOR MYTHTVUxRTR4OT65xtE5QCEQvF2= M{XFPVI2Ojd5NESx
SNB19VR NVXmZnBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV63JIQ> MkO0SG1UVw>? NG\vU4lIUTVyPUK4NE4zyrFzODFOwG0> M2fMclI2Ojd5NESx
U373V MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[3JIQ> Moi3SG1UVw>? NH7CT5ZIUTVyPU[4MlDDuTN{IN88US=> NUnPeWltOjV{N{e0OFE>
U373M MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWi3JIQ> NYfqNZJkTE2VTx?= MYjHTVUxRTN4OD63xtE5PiEQvF2= NIPzOFAzPTJ5N{S0NS=>
U373VR MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX:3JIQ> M2\G[WROW09? M1zacWdKPTB;Mki4MljDuTN|IN88US=> MoLwNlUzPzd2NEG=
U87MG M3\GR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVv4UnU3PyCm M{HGRWROW09? M1Lud2dKPTB;M{iuN:KyOjBizszN MWOyOVI4PzR2MR?=
HCT116 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUi3JIQ> MVXEUXNQ MnrJS2k2OD13N{muPeKyOzJizszN NHjDNVQzPTJ5N{S0NS=>
DLD1 NVuzNFd{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTLUHFGPyCm NVi3TFRWTE2VTx?= NHu5[5ZIUTVyPUWwNU41yrF7MzFOwG0> NWTJV|NSOjV{N{e0OFE>
MRC5 M4j4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe4cGc4KGR? NWfLV3I6TE2VTx?= NE\zOWxIUTVyPUS0PU41yrF6IN88US=> MV:yOVI4PzR2MR?=
SNB19V  M1;Bc2Z2dmO2aX;uJGF{e2G7 NFrRUZgyODBizszNxsBVVVp? MXiwMVczKGh? NWLXe5lMcW6lcnXhd4V{KM7|SELBXEBmgHC{ZYPzbY9vKGKndIfl[Y4hOTZiYX7kJFczKGh? M3;pbVI2Ojd5NESx
T98G  NXfoNosyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXJNmpIPS9zMD:xOUDPxE1? M1XrSVI1yqCq MoPEbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= M4nrUlI2OjZ{OU[x
U251  NV7oXIVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO1M|ExNzF3IN88US=> M{TUWlI1yqCq NF;BXoZqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> NYTKZXlCOjV{NkK5OlE>
T98G  NHfaTnZHfW6ldHnvckBCe3OjeR?= NYLhRnBJOTVizszN M1nySlI1yqCq NYHoTGIzcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz MoP4NlUzPjJ7NkG=
U251  NVXZN4gxTnWwY4Tpc44hSXO|YYm= M2nmVFE2KM7:TR?= MmS4NlTDqGh? NYWyVXpMcW6lcnXhd4V{KESQQT3mdoFodWWwdHH0bY9vKGmwIF7Q[VYuWESWIITy[YF1\WRiZ3zpc41iKGOnbHzz M3HYW|I2OjZ{OU[x
U-87 MG M2LPdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmm1O|IhcA>? NWjrNY1QUUN3ME2wMlk{KG2PwrC= M4fnWlI2OjR3M{Oy
U-118 MG NYLTcXVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mom2O|IhcA>? NIPWb5pKSzVyPUGuNFUhdU4EoB?= NITDUnUzPTJ2NUOzNi=>
U87 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnGVFFsOjRiaB?= MnS1TWM2OD1{NkCuN|Qh|ryPwrC= M4LXb|I2OTd|MkOz
U87 GSLCs NHz5fG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIn3eWIzPCCq NGCwcI1KSzVyPUe2Ok4yOSEQvF5CpC=> MYCyOVE4OzJ|Mx?=
U87MG NXPGSmIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWS2b2RGPzJiaB?= MWnJR|UxRTF3Lk[yOUDPxE4EoB?= MX6yOVA2ODlzNR?=
U251 NEHoVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonRNVAxNTRyMDFOwG0> NU\TXpN4PDhiaB?= M4LuXGROW09? M2PybYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NVT1O3A1OjR4MkO3N|Y>
U87 M{fTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW3ZXNxOTByLUSwNEDPxE1? M4\RcFQ5KGh? NXXqPYd5TE2VTx?= MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYTRSHlIOjR4MkO3N|Y>
MDA-MB-231-br NH64d5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCwMVExKM7:TR?= NXHIPYpLPDhiaB?= M{LlV2ROW09? NEKzXGxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NUnMbVd1OjR4MkO3N|Y>
HCC-1937 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7RNmgxNTNyMDFOwG0> NVG4NZhMPDhiaB?= M{TtT2ROW09? MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIm4ZWMzPDZ{M{ezOi=>
MDA-MB-231 Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYGwMVQxKM7:TR?= MWW0PEBp NGfSUmhFVVOR NHXibJBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIflV2QzPDZ{M{ezOi=>
MDA-MB-468 M1GxVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7m[o16OC13MECg{txO MUi0PEBp Moi1SG1UVw>? MV7pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NGTY[5QzPDZ{M{ezOi=>
T47D NVfPc44yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXKyO4M5OC1zMECg{txO NELUXWw1QCCq NGnN[mtFVVOR NUG1bHI2cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Mm\YNlQ3OjN5M{[=
MCF7 NUPlWpFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnRNXJqOC1zMECwJO69VQ>? NVvPe4ZHPDhiaB?= MWrEUXNQ MnjLbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NFHpbIEzPDZ{M{ezOi=>
Hs683 NHjTd5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLYNE0yODByIN88US=> MYe5OkBp MUXJR|UxRTF{OD65JO69VQ>? NGDOV3UzPDR7NUmwOy=>
U87 NHPB[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETl[mIxNTFyMECg{txO M{fhcFk3KGh? MljXTWM2OD1zOD60OUDPxE1? Mn7iNlQ1QTV7MEe=
LNZ308 Ml3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTNNE0yODByIN88US=> NG\ENHY6PiCq NGXZd5RKSzVyPUOyOk44KM7:TR?= MVuyOFQ6PTlyNx?=
U87 MWDBdI9xfG:|aYOgRZN{[Xl? MV2xNFAh|ryP NVLkZlFZPDhiaB?= MVzEUXNQ NHHRfWxqdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5 MnHmNlQ1QDF3OE[=
U251  MWHBdI9xfG:|aYOgRZN{[Xl? NHP1TFgyODBizszN NFXwVHE1QCCq M3n4dGROW09? NWjadoVRcW6lcnXhd4V{KHSqZTDjZZNx[XOnLUOvO{Bi[3Srdnn0fS=> M2jMeFI1PDhzNUi2
U251 NVjjZohtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mwbVI1KGh? NXTselc1UUN3ME24Ok4zQeLCidMx5qCKOS53ODFOwG0> MoLDNlQ{OjZ7NUS=
U251 NG\CUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlyxOFghcA>? NVXR[lllUUN3ME23OU4{POLCidMx5qCKOS5yMjFOwG0> MnHXNlQ{OjZ7NUS=
U251 M2X2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX:3NkBp MWDJR|UxRTd{LkSy5qCKyrIkgJmxMlQ2KM7:TR?= MkH2NlQ{OjZ7NUS=
U251 M2\zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPzN2ZbQTZiaB?= NUDyVYVOUUN3ME22PU45OuLCidMx5qCKOy5yNDFOwG0> NGTsPYwzPDN{Nkm1OC=>
T98G NHfvWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWOwMVc2OCEQvF2= MY[3Nk86PiCq NVnKO4U2cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NIr1ZXUzPDN{NEC4NC=>
U251-MG NW[2OWNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1GzVlAuQDByIN88US=> MlvVO|IhcA>? NUPjOmRocW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MmrBNlQxQTN4M{C=
D54-MG MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[3V|kxNThyMDFOwG0> MlKxO|IhcA>? NIDzeXlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MoK4NlQxQTN4M{C=
SHG-44 MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVuxNE0zODBizszN MUC5OkBp MkLDTWM2OD17LkezJOKyKDJwMUKg{txO MUKyOFA3PTV4OR?=
U373  M3XtNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7LNVAuOjByIN88US=> M3HLVlk3KGh? NHTkT5ZKSzVyPUGwMlE{KMLzIEGuNFIh|ryP MoTONlQxPjV3Nkm=
HT-29  NECzTFdHfW6ldHnvckBCe3OjeR?= MnmxOVAxKM7:TR?= NUfTOJk4OjRxNEigbC=> NYTwWlR4\W6qYX7j[ZMhfGinIHzleoVteyCxZjFOt{1JOkG[wrC= MVKyOFA{QDB4OB?=
PC-3  NV7ocpJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnId4ZZOC1{NTFOwG0> MUG0PEBp NFi2bGhqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWgdI91\W62aXH0[YQh[nlibInjc5BmdmV? M2rYclI{PzR4OUO0
PC-3  NV7nPZJFSXCxcITvd4l{KEG|c3H5 M4P0U|I2KM7:TR?= M3PNZ|Q5KGh? NXywcHpycW6mdXPld{BieG:ydH;zbZMhf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m MYmyN|c1Pjl|NB?=
T98G NYHGXmJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[1NE01ODBizszN NUfwOmVuOTR2IHi= MYjpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MkflNlM4OTV2OUm=
U87-MG MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jNPVExOCEEtV2= MWi3NkBp MnOxbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>? M4\TWVI{Pjl4N{i4
U251-MG NX[2bGFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLMenMyODBiwsXN NWHjNGQ2PzJiaB?= NVK4RnFGcW6qaXLpeJMh[2WubDDndo94fGhid3jpZ4gh[2GwIHLlJIVvcGGwY3XkJIJ6KEeWQh?= M1fnSVI{Pjl4N{i4
LNT-229 MnPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2j5bFMuOTByIN88US=> MVGyOEBp MkX5bY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXjlUHZyOjN4Nke2N|I>
T98G NY\XcXFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSxNE04ODBizszN NF7kUWUzPCCq MkfTbY5pcWKrdIOgZ4xwdm:pZX7pZ{B{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUKyN|Y3PzZ|Mh?=
U87  NUDrdGl{TnWwY4Tpc44hSXO|YYm= MXyxNFAhyrWP Mk\pN{Bp NEH2dlBmdGW4YYTld{B1cGVibHX2[Yx{KG:oIIDDbIsyKGGwZDDwR4hsOg>? M1HaWlI{PjZ5NE[5
HCT116 MnP1SpVv[3Srb36gRZN{[Xl? MVSxNFAhyrWP MnXCN{Bp NXfNNYp4cW6mdXPld{B1cGViQ3jrNUBRcG:|cHjvdplt[XSrb36= NEO2blYzOzZ4N{S2PS=>
HCT3-6 NHuxeXpHfW6ldHnvckBCe3OjeR?= M4PUPFExOCEEtV2= NEHhTmM{KGh? NGDV[2dqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= M1rLblI{PjZ5NE[5
U-87  NVjr[ItwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPmNE01OCEQvF2= Moq0NVIh\A>? NXLnTHhxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEHwWVAzOzZ2NUeyPS=>
U-87  MW\BdI9xfG:|aYOgRZN{[Xl? NVfWXWxvOC12MDFOwG0> NIjlcGk{NzZiZB?= NV3uUJZNcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEBld3OnLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MWeyN|Y1PTd{OR?=
U-87  MlnoSpVv[3Srb36gRZN{[Xl? MnHiNE01OCEQvF2= MW[zM|Yh\A>? MYDpcoR2[2W|IHH1eI9xcGGpeTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NWPX[GxZOjN4NEW3Nlk>
GB-SCC010 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1L4clQh\A>? MnvPTWM2OD1{Mk[g{txO NFfMT|EzOzZzMke1OS=>
GB-SCC026 NEC4N3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\BfFQh\A>? NULKSm9MUUN3ME21N{4yKM7:TR?= MUiyN|YyOjd3NR?=
GB-SCC028 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPCOEBl Mn[xTWM2OD1zNkeg{txO M4[3U|I{PjF{N{W1
U87 NHTCbXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLP[YU4PCCm M2\CRWlEPTB;NEWuNkDPxE1? MnLnNlM3OTJ5NUW=
U87 stem cell MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF:3eGw1KGR? M2nCPWlEPTB;Nk[uO{DPxE1? NHHHXnkzOzZzMke1OS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pERK / ERK / p-p38 / p38; 

PubMed: 24436439     


Cells were treated with TMZ (0.5 mM) time dependently, and Western blotting was used to analyze for phosphorylated ERK and p38 MAPK expression.

DR5 / c-FLIP / Survivin / XIAP; 

PubMed: 24436439     


Western blot analysis showing expressions in DR5 and antiapoptotic proteins (c-FLIP, survivin, and XIAP) in glioma cells treated with increasing doses of TMZ (0–2 mM) for 24 hours. 

24436439
Growth inhibition assay
Cell viability; 

PubMed: 25751281     


Distinct temozolomide-resistance for MGMT-expressing (SF767) and MGMT-negative (U87) GBM cells was assessed.

25751281
Immunofluorescence
Phalloidin / Phospho-H2A.X; 

PubMed: 27375225     


Immunofluorescence analysis of the level of phospho-H2A.X in nucleus which can reflect DNA damage response increased significantly at day 6, peaked during days 7-10 and decreased significantly at day 12 after treatment temozolomide (200 μM). 

cleaved caspase-3; 

PubMed: 25663820     


Representative Photomicrographs of cleaved caspase-3 immunoreactivity in control (DMSO treated) and treated group of U87 cells. Base line immunofluorescence was detected in control group. Significant Increase in immunofluorescence is detected in all treated groups with the highest observed intensity in combination treatment group (NA-2 + TMZ).

27375225 25663820
体内研究 每天腹腔注射40 mg/kg,连续5天(肿瘤移植后1-5天)后,在L-1210 和L-1210/BCNU中,methazolastone分别增加86%和22%的寿命。在L-1210/BCNU中,100 μM 或200 μM治疗后没有作用,仅400 μM methazolastone使细胞在有丝分裂前期产生积聚,但是在L-1210中效果较弱。在L-1210/BCNU中,SL-G2-M期细胞的最大积聚在48-72小时后,大约为30%,未处理的细胞为23%。患有L- 1210白血病的小鼠静脉注射methazolastone (40 mg/kg)时,也会使细胞在SL-G2-M期积聚。而给予相同剂量药物的小鼠L-1210/BCNU细胞中,没有此作用。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

+ 展开
  • Cell lines: L-1210 和 L-1210/BCNU 细胞
  • Concentrations: 0 μM -100 μM
  • Incubation Time: 1小时
  • Method:

    L-1210和L-1210/ BCNU细胞以0.2×104 cells/mL接种,并培养24小时。培养基用Methazolastone在37℃下处理1小时,然后用PBS洗涤两次,离心并重新悬浮在新鲜培养基中。对照组和处理试样在48小时时以1:4在新鲜培养基中稀释,第96小时时,以1:2稀释。整个实验中使用这些稀释的细胞浓度介于3×105和8×105/mL之间。该范围内对照组呈对数生长。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 负荷L-1210 和 L-1210/BCNU细胞的DBA/2小鼠
  • Formulation: 95%乙醇
  • Dosages: 40 mg/kg
  • Administration: 静脉注射给药
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
2mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 194.15
化学式

C6H6N6O2

CAS号 85622-93-1
稳定性 powder
in solvent
别名 CCRG81045, NSC 362856

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03687034 Not yet recruiting Glioblastoma Leaf Vertical Inc. June 1 2019 Phase 1
NCT03776071 Not yet recruiting Glioblastoma Denovo Biopharma LLC June 2019 Phase 2
NCT03776071 Not yet recruiting Glioblastoma Denovo Biopharma LLC June 2019 Phase 2
NCT03880019 Not yet recruiting Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 National Cancer Institute (NCI) June 7 2019 Phase 2
NCT03880019 Not yet recruiting Stage III Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8|Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8|Stage IV Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8|Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8 National Cancer Institute (NCI) June 7 2019 Phase 2
NCT03687034 Not yet recruiting Glioblastoma Leaf Vertical Inc. June 1 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

DNA/RNA Synthesis Signaling Pathway Map

相关DNA/RNA Synthesis产品

Tags: 购买Temozolomide | Temozolomide ic50 | Temozolomide价格 | Temozolomide DMSO溶解度 | 采购Temozolomide | Temozolomide生产 | Temozolomide 小鼠 | Temozolomide化学结构 | Temozolomide分子量 | Temozolomide molecular weight | Temozolomide说明书 | Temozolomide供应商 | Temozolomide体内 | Temozolomide细胞系 | Temozolomide浓度 | Temozolomide nmr | Temozolomide核磁 | Temozolomide半数抑制浓度 | Temozolomide体外
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID